Viatris Company Profile

✉ Email this page to a colleague

VIATRIS has twenty-seven approved drugs.

There are five US patents protecting VIATRIS drugs.

There are fifty-seven patent family members on VIATRIS drugs in twenty-five countries and one hundred and forty-one supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	ELESTRIN	estradiol	GEL, METERED;TRANSDERMAL	021813-001	Dec 15, 2006		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Viatris Specialty	GASTROCROM	cromolyn sodium	CONCENTRATE;ORAL	020479-001	Feb 29, 1996	AA	RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-002	Dec 30, 1993	AB	RX	Yes	No		⤷ Start Trial				⤷ Start Trial
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-004	Nov 19, 1996		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	EPIPEN	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	019430-001	Dec 22, 1987	8,048,035	⤷ Start Trial
Viatris	GEODON	ziprasidone hydrochloride	CAPSULE;ORAL	020825-002	Feb 5, 2001	5,312,925	⤷ Start Trial
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-003	Dec 30, 1991	5,744,501	⤷ Start Trial
Viatris	EPIPEN JR.	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	019430-002	Dec 22, 1987	8,870,827	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	20 mg, 40 mg, 60 mg and 80 mg	➤ Subscribe	2005-02-07
➤ Subscribe	Injection (Auto-injector)	0.15 mg/0.3 mL and 0.3 mg/0.3 mL	➤ Subscribe	2008-11-21
➤ Subscribe	Inhalation Solution	300 mg/5 mL	➤ Subscribe	2009-06-29
➤ Subscribe	Tablets	25 mg and 50 mg	➤ Subscribe	2004-11-19
➤ Subscribe	Sublingual Tablets	5 mg and 10 mg	➤ Subscribe	2010-04-29
➤ Subscribe	Sublingual Tablets	0.6 mg	➤ Subscribe	2011-12-29
➤ Subscribe	Tablets	150 mg and 200 mg	➤ Subscribe	2005-11-09
➤ Subscribe	Injection (Auto-injector)	0.15 mg/0.3 mL and 0.3 mg/0.3 mL	➤ Subscribe	2008-11-21
➤ Subscribe	Nasal Spray	205.5 mcg/spray	➤ Subscribe	2011-12-15
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2004-10-25
➤ Subscribe	Sublingual Tablets	0.3 mg, 0.4 mg and 0.6 mg	➤ Subscribe	2005-10-19
➤ Subscribe	CapsulesInhalation Solution	0.02 mg/2 mL	➤ Subscribe	2009-01-21

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0584952	99C0004	Belgium	⤷ Start Trial	PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306
1280520	92678	Luxembourg	⤷ Start Trial	PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725
0473687	99C0008	Belgium	⤷ Start Trial	PRODUCT NAME: FOSPHENYTOINUM DINATRICUM; REGISTRATION NO/DATE: 19 IS 102 F12 19980901; FIRST REGISTRATION: GB PL00019/1057 19980204
2435024	C02435024/01	Switzerland	⤷ Start Trial	PRODUCT NAME: BUDESONID, GLYCOPYRRONIUM UND FORMOTEROL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68388 24.11.2021
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.